What is Diagnostic Robotics?
Diagnostic Robotics is a specialized HealthTech enterprise focused on optimizing healthcare efficiency through sophisticated AI-driven solutions. At the core of its product suite is Maxine, a virtual assistant designed to automate complex administrative tasks, streamline communication between payers and providers, and improve patient engagement. By addressing critical pain points such as medication adherence and appointment scheduling, the company provides essential tools for Accountable Care Organizations (ACOs) to maximize value-based care outcomes. The firm operates at the intersection of clinical research and operational technology, aiming to reduce systemic costs while fostering more meaningful interactions between patients and their care teams.
How much funding has Diagnostic Robotics raised?
Diagnostic Robotics has raised a total of $69M across 2 funding rounds:
Series A
$24M
Series B
$45M
Series A (2019): $24M with participation from Mivtach Shamir Holdings, Accelmed, Alpha Capital Partners, and Maverick Ventures Israel
Series B (2022): $45M led by Bank Hapoalim, Clal Insurance, Midgal Insurance, Mayo Clinic, and StageOne Ventures
Key Investors in Diagnostic Robotics
Mayo Clinic
A nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research with a focus on complex patient care.
StageOne Ventures
A venture capital firm specializing in leading investments in early-stage, Israel-related deep tech startups that address complex enterprise challenges.
Mivtach Shamir Holdings
A venture capital and private equity firm specializing in investments in technology, communications, and industrial companies with a focus on turnaround strategies.
What's next for Diagnostic Robotics?
With the recent infusion of capital, Diagnostic Robotics is positioned to accelerate its market penetration and enhance its technological infrastructure. The strategic focus will likely shift toward scaling the deployment of its AI solutions across larger health systems and refining its predictive analytics capabilities. Given the involvement of major institutional investors and clinical partners, the company is well-equipped to navigate the complexities of the healthcare regulatory environment while maintaining its trajectory as a leader in digital health innovation. Future growth will likely center on expanding the reach of its virtual assistant platform to address broader patient populations and further integrating its services into the standard of care for global health organizations.
See full Diagnostic Robotics company page
